

# John B A G Haanen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/423437/publications.pdf>

Version: 2024-02-01

389  
papers

69,011  
citations

5126

86  
h-index

832

252  
g-index

408  
all docs

408  
docs citations

408  
times ranked

60028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 248-255.	2.0	9
2	Survival of stage IV melanoma in Belgium and the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
3	Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	2.3	12
4	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	1.3	7
5	The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , 2022, 150, 816-824.	2.3	18
6	BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA. <i>Retinal Cases and Brief Reports</i> , 2022, 16, 430-434.	0.3	7
7	Cytoreductive nephrectomy and exposure to sunitinib—a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. <i>BJU International</i> , 2022, 130, 68-75.	1.3	12
8	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747.	3.2	11
9	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
10	Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. <i>European Urology Open Science</i> , 2022, 35, 54-58.	0.2	15
11	The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series. <i>ESMO Open</i> , 2022, 7, 100374.	2.0	24
12	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
13	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
14	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80.	1.3	19
15	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
16	[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2010-2022.	3.3	11
17	18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients. <i>Clinical Nuclear Medicine</i> , 2022, 47, 583-589.	0.7	4
18	Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. <i>Lancet Oncology</i> , The, 2022, 23, 833-835.	5.1	18

#	ARTICLE	IF	CITATIONS
19	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	15.2	121
20	Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 189-203.	1.8	7
21	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. <i>Melanoma Research</i> , 2022, 32, 460-468.	0.6	7
22	MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. <i>Immuno-Oncology Technology</i> , 2022, 15, 100089.	0.2	9
23	TIL classified to memory state are correlated with response to immune checkpoint blockade. <i>Cell Reports Medicine</i> , 2022, 3, 100669.	3.3	0
24	Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. <i>Clinica Chimica Acta</i> , 2022, 533, 71-78.	0.5	4
25	Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9607-TPS9607.	0.8	0
26	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 274.e1-274.e16.	0.9	12
27	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
28	Cellular Therapy and Cytokine Treatments for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 129-144.	0.9	11
29	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1227-1237.	2.0	23
30	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
31	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , 2021, 124, 1222-1230.	2.9	16
32	An open-label phase II study comparing two doses of MK-6482 for the treatment of advanced renal cell carcinoma (RCC) following progression on prior systemic therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS369-TPS369.	0.8	0
33	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. <i>European Journal of Cancer</i> , 2021, 144, 242-251.	1.3	16
34	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021, 27, 568-569.	15.2	53
35	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , 2021, 15, 510-519.	1.9	14
36	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263.	15.2	190

#	ARTICLE	IF	CITATIONS
37	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021, 21, 323.	1.1	22
38	The power to â€œedi-sc-seq-tâ€™. <i>Cancer Cell</i> , 2021, 39, 299-301.	7.7	0
39	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
40	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , 2021, 6, 100058.	2.0	47
41	Neoadjuvant Cyto-reductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	2.1	28
42	Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21523-e21523.	0.8	0
43	Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4548-4548.	0.8	4
44	Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4574-4574.	0.8	17
45	Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18641-e18641.	0.8	0
46	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 641-648.	2.0	46
47	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4547-4547.	0.8	0
48	Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4573-4573.	0.8	1
49	IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel;) Tj ETQq1 1 0.784314 rgBT /Overlock (Substudies 1 and 2).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11582-TPS11582.	0.8	5
50	<i>BRAF</i> and <i>NRAS</i> mutation status and response to checkpoint inhibition in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9558-9558.	0.8	0
51	Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9544-9544.	0.8	0
52	Dutch advanced melanoma care in times of COVID-19.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21502-e21502.	0.8	1
53	Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1â€™specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	5
54	A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4597-TPS4597.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Efficacy of checkpoint inhibition in advanced acral melanoma.. Journal of Clinical Oncology, 2021, 39, e21527-e21527.	0.8	0
56	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. Journal of Clinical Oncology, 2021, 39, 9506-9506.	0.8	101
57	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers, 2021, 13, 3083.	1.7	9
58	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	1.7	11
59	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	0.6	22
60	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
61	Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4. Clinical Cancer Research, 2021, 27, 5389-5400.	3.2	3
62	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	15.2	159
63	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. ESMO Open, 2021, 6, 100199.	2.0	19
64	HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. , 2021, 9, e002547.		11
65	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. Journal of Geriatric Oncology, 2021, 12, 1031-1038.	0.5	2
66	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	1.7	9
67	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003â€“2018): A nationwide population-based study. European Journal of Cancer, 2021, 154, 111-119.	1.3	16
68	Adjuvant treatment for melanoma in clinical practice â€“ Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	1.3	12
69	LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors. Annals of Oncology, 2021, 32, S1337.	0.6	10
70	Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry. European Journal of Cancer, 2021, 156, 24-34.	1.3	29
71	Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. European Journal of Cancer, 2021, 157, 225-237.	1.3	9
72	T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-Î³, TNF-Î± or IL-2 production. Oncoimmunology, 2021, 10, 1860482.	2.1	16

#	ARTICLE	IF	CITATIONS
73	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 82-89.	0.6	2
74	Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1
75	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.3	2
76	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
77	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. Melanoma Research, 2021, 31, 58-66.	0.6	6
78	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells. Cell Reports, 2021, 37, 110013.	2.9	38
79	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1681-1691.	5.1	118
80	Immunotherapy for cancer treatment during pregnancy. Lancet Oncology, The, 2021, 22, e550-e561.	5.1	37
81	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open, 2021, 6, 100320.	2.0	10
82	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature Communications, 2021, 12, 7348.	5.8	96
83	New milestones for IOTTECH in 2022. Immuno-Oncology Technology, 2021, 12, 100060.	0.2	0
84	Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. Journal of Geriatric Oncology, 2020, 11, 529-532.	0.5	0
85	Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. Pigment Cell and Melanoma Research, 2020, 33, 498-506.	1.5	11
86	Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Research, 2020, 30, 252-260.	0.6	37
87	A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. International Journal of Cancer, 2020, 147, 1143-1151.	2.3	16
88	Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis. Journal of Thoracic Oncology, 2020, 15, e15-e20.	0.5	9
89	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
90	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	0.6	132

#	ARTICLE	IF	CITATIONS
91	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020, 5, e000945.	2.0	14
92	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	1.3	65
93	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study. <i>European Journal of Cancer</i> , 2020, 137, 127-135.	1.3	14
94	Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness. <i>BMC Cancer</i> , 2020, 20, 712.	1.1	15
95	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , 2020, 12, 2072.	1.7	16
96	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. , 2020, 8, e000848.		79
97	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69
98	Conserved Interferon- $\gamma$ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	7.7	203
99	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	15.2	282
100	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , 2020, 43, 256-264.	1.2	17
101	1097P 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma: OpACIN trial. <i>Annals of Oncology</i> , 2020, 31, S742-S743.	0.6	5
102	LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. <i>Annals of Oncology</i> , 2020, 31, S1169.	0.6	12
103	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136.	0.5	82
104	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
105	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
106	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
107	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>OncImmunity</i> , 2020, 9, 1738814.	2.1	13
108	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor- $\alpha$ -targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020, 3, 168-173.	2.6	25



#	ARTICLE	IF	CITATIONS
109	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. <i>Nature Medicine</i> , 2020, 26, 566-576.	15.2	736
110	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	1.7	15
111	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274.	3.2	112
112	The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. <i>Clinical Cancer Research</i> , 2020, 26, 4289-4301.	3.2	46
113	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials. <i>Cancer Research</i> , 2020, 80, 3412-3412.	0.4	8
114	Cancer management in the era of immunotherapy: much more than meets the eye. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 141-142.	0.4	1
115	Prognostic and predictive role of the tumor immune landscape. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 143-151.	0.4	3
116	Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma. , 2020, , 1109-1140.		0
117	Immunotherapie van kanker. , 2020, , 191-201.		0
118	Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME.. <i>Journal of Clinical Oncology</i> , 2020, 38, 703-703.	0.8	0
119	Cryoablation and immunotherapy: an overview of evidence on its synergy. <i>Insights Into Imaging</i> , 2019, 10, 53.	1.6	89
120	A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). <i>Future Oncology</i> , 2019, 15, 2203-2209.	1.1	19
121	Transgenerational transfer of gene-modified T cells. , 2019, 7, 186.		5
122	Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019, 11, 1007.	1.7	22
123	EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy. <i>Annals of Oncology</i> , 2019, 30, v528.	0.6	0
124	Deep learning radiomics distinguishes intrapulmonary disease from metastases in immunotherapy-treated melanoma patients. <i>Annals of Oncology</i> , 2019, 30, v529.	0.6	1
125	Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, v553.	0.6	0
126	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	1.3	27



#	ARTICLE	IF	CITATIONS
127	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472.	2.0	26
128	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. <i>European Journal of Cancer</i> , 2019, 123, 58-71.	1.3	45
129	Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma. <i>Annals of Oncology</i> , 2019, 30, v481-v482.	0.6	4
130	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	1.3	61
131	Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1545-1552.	2.8	19
132	Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile. <i>Oncolmmunology</i> , 2019, 8, e1648170.	2.1	36
133	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
134	Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). <i>European Urology</i> , 2019, 76, 437-440.	0.9	29
135	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	5.1	346
136	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
137	Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. <i>Journal of Biotechnology</i> , 2019, 306, 100007.	1.9	12
138	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	15.2	589
139	Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. <i>Annals of Oncology</i> , 2019, 30, 998-1004.	0.6	361
140	Glutamyl cyclase is an enzymatic modifier of the CD47- SIRP1± axis and a target for cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 612-619.	15.2	156
141	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. <i>Oncolmmunology</i> , 2019, 8, 1558664.	2.1	0
142	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
143	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
144	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 787-798.	2.0	2

#	ARTICLE	IF	CITATIONS
145	How I treat MSI cancers with advanced disease. ESMO Open, 2019, 4, e000511.	2.0	23
146	Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs. ESMO Open, 2019, 4, e000557.	2.0	2
147	OP0165â€¦EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY. , 2019, , .		0
148	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. Cancers, 2019, 11, 1940.	1.7	29
149	Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology. Otolaryngology and Neurotology, 2019, 40, e674-e678.	0.7	30
150	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell, 2019, 176, 775-789.e18.	13.5	760
151	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 319-329.	2.0	11
152	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. Cancer Immunology Research, 2019, 7, 77-85.	1.6	114
153	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2019, 7, 6-11.	1.6	118
154	Adoptive cellular therapies: the current landscape. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 449-461.	1.4	261
155	The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. Cancer Immunology, Immunotherapy, 2019, 68, 503-515.	2.0	26
156	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. JAMA Oncology, 2019, 5, 164.	3.4	329
157	Characterisation of rare haematological immune-related toxicities. Lancet Haematology,the, 2019, 6, e10-e11.	2.2	0
158	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nature Medicine, 2019, 25, 89-94.	15.2	413
159	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 101-101.	0.8	75
160	Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).. Journal of Clinical Oncology, 2019, 37, 2575-2575.	0.8	17
161	Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.. Journal of Clinical Oncology, 2019, 37, 9587-9587.	0.8	5
162	Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 544-544.	0.8	13

#	ARTICLE	IF	CITATIONS
163	Cytokines (IL-2, IFN GM-CSF etc) Melanoma. , 2019, , 1-31.		0
164	Abstract B022: Properties of T-cell-recognized neoantigens. , 2019, , .		1
165	Abstract B205: Adoptive transfer of autologous T-cells, modified with a MART-1 specific TCR and cultured in IL-7/IL-15, for the treatment of metastatic melanoma patients. , 2019, , .		0
166	Abstract A185: Effective expansion of poly-functional tumor-reactive TILs from NSCLC correlates with an immune-engaged T-cell profile in tumor tissues. , 2019, , .		0
167	Abstract B050: Identification of PD-1 TILs and CXCL13 as determinants for response to anti-PD-1 treatment using human tumor explants. , 2019, , .		0
168	Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM). , 2019, , .		0
169	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	0.7	11
170	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	0.7	11
171	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. <i>ESMO Open</i> , 2018, 3, e000278.	2.0	197
172	Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. <i>Melanoma Research</i> , 2018, 28, 126-133.	0.6	31
173	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317.	3.3	78
174	Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product. <i>Journal of Immunotherapy</i> , 2018, 41, 413-425.	1.2	10
175	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018, 3, e000422.	2.0	50
176	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). <i>Annals of Oncology</i> , 2018, 29, viii465-viii466.	0.6	3
177	NKG2A, a New Kid on the Immune Checkpoint Block. <i>Cell</i> , 2018, 175, 1720-1722.	13.5	83
178	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nature Medicine</i> , 2018, 24, 1655-1661.	15.2	599
179	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018, 3, e000423.	2.0	35
180	Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. , 2018, 6, 102.		141

#	ARTICLE	IF	CITATIONS
181	Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. BMC Cancer, 2018, 18, 895.	1.1	17
182	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 2018, 28, 326-332.	0.6	8
183	Cytoreductive nephrectomy in metastatic renal cancer "less is more. Nature Reviews Clinical Oncology, 2018, 15, 595-596.	12.5	3
184	Questions asked in the everyday practice: immune checkpoint inhibitors. ESMO Open, 2018, 3, e000395.	2.0	1
185	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell, 2018, 174, 1586-1598.e12.	13.5	644
186	Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N161MC, NCT03003637).. Journal of Clinical Oncology, 2018, 36, e18020-e18020.	0.8	3
187	A phase 2, single-arm trial of neoadjuvant axitinib plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. Journal of Clinical Oncology, 2018, 36, TPS4604-TPS4604.	0.8	2
188	Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, TPS9602-TPS9602.	0.8	1
189	Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.. Journal of Clinical Oncology, 2018, 36, 4572-4572.	0.8	0
190	Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.. Journal of Clinical Oncology, 2018, 36, 9585-9585.	0.8	0
191	Abstract 4693: Characterization of the tumor immune microenvironment in head and neck squamous cell carcinoma (SCCHN). Cancer Research, 2018, 78, 4693-4693.	0.4	1
192	Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. Cancer Immunology Research, 2017, 5, 170-179.	1.6	23
193	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis, 2017, 20, 205-215.	3.7	59
194	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	0.6	549
195	HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunology, Immunotherapy, 2017, 66, 1163-1173.	2.0	17
196	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer, 2017, 82, 45-55.	1.3	160
197	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. JAMA Oncology, 2017, 3, 501.	3.4	23
198	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 2017, 72, 156-165.	1.3	77

#	ARTICLE	IF	CITATIONS
199	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
200	Converting Cold into Hot Tumors by Combining Immunotherapies. <i>Cell</i> , 2017, 170, 1055-1056.	13.5	212
201	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. <i>Annals of Oncology</i> , 2017, 28, 862-867.	0.6	13
202	Fixed Dosing of Monoclonal Antibodies in Oncology. <i>Oncologist</i> , 2017, 22, 1212-1221.	1.9	114
203	Observation After Cyto-reductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. <i>Urology</i> , 2017, 109, 127-133.	0.5	8
204	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv119-iv142.	0.6	1,744
205	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw192.	3.0	296
206	Clinical Pharmacokinetics of Vemurafenib in BRAF $\mu$ Mutated Melanoma Patients. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 125-128.	1.0	14
207	Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 188-192.	0.5	19
208	Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). <i>Annals of Oncology</i> , 2017, 28, v622.	0.6	17
209	Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. <i>BMC Cancer</i> , 2017, 17, 649.	1.1	12
210	Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker. <i>Journal of Clinical Oncology</i> , 2017, 35, 3794-3795.	0.8	1
211	Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial. <i>Annals of Oncology</i> , 2017, 28, v431.	0.6	0
212	Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038. , 2017, , .		4
213	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). <i>Cancer Research</i> , 2017, 77, CT075-CT075.	0.4	34
214	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	0.8	17
215	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9539-9539.	0.8	4
216	Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9586-9586.	0.8	23

#	ARTICLE	IF	CITATIONS
217	Immune checkpoint inhibition-related colitis: Correlation between ulcers and need for infliximab.. Journal of Clinical Oncology, 2017, 35, e21062-e21062.	0.8	2
218	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. Journal of Clinical Oncology, 2017, 35, TPS4594-TPS4594.	0.8	15
219	Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.. Journal of Clinical Oncology, 2017, 35, 514-514.	0.8	0
220	Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.. Journal of Clinical Oncology, 2017, 35, 9572-9572.	0.8	0
221	Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. BMC Cancer, 2016, 16, 364.	1.1	8
222	The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology, 2016, 56, 1307-1312.	1.0	26
223	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277.	2.9	61
224	Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. European Journal of Immunology, 2016, 46, 1351-1360.	1.6	31
225	Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib) Tj ETQq1 1 0,784314 rgBT /Ov 0,1	0.1	0
226	The "cancer immunogram" Science, 2016, 352, 658-660.	6.0	655
227	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology, 2016, 91, 267-273.	0.9	10
228	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. Prostate, 2016, 76, 32-40.	1.2	13
229	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology, 2016, 5, e1238557.	2.1	113
230	Single center experience on patients with advanced melanoma treated with short-term anti-CTLA4 directly followed by anti-PD-1. Annals of Oncology, 2016, 27, vi384.	0.6	0
231	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	1.8	12
232	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). Annals of Oncology, 2016, 27, vi386.	0.6	5
233	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncoimmunology, 2016, 5, e1201625.	2.1	21
234	Neoantigen landscape dynamics during human melanoma "T cell interactions. Nature, 2016, 536, 91-95.	13.7	387



#	ARTICLE	IF	CITATIONS
235	Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. <i>World Journal of Urology</i> , 2016, 34, 1067-1072.	1.2	21
236	Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 258.e7-258.e13.	0.8	6
237	Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. <i>Annals of Oncology</i> , 2016, 27, 1138-1142.	0.6	68
238	The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3026-3026.	0.8	3
239	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9505-9505.	0.8	50
240	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9526-9526.	0.8	2
241	Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9592-TPS9592.	0.8	3
242	Time to targeted therapy after cytoreductive nephrectomy (CN) and surveillance in patients with synchronous unresectable metastases of renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 604-604.	0.8	4
243	Retrospective analysis of patients with advanced melanoma treated with short course of anti-CTLA4 directly followed by anti-PD-1.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21011-e21011.	0.8	0
244	Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2016, 34, e21058-e21058.	0.8	0
245	A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4550-4550.	0.8	1
246	Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions. , 2016, , .		0
247	Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. <i>EMBO Molecular Medicine</i> , 2015, 7, 1104-1118.	3.3	129
248	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
249	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	6.3	1,175
250	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <i>Ophthalmology</i> , 2015, 122, 1907-1916.	2.5	69
251	NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 32.	1.8	81
252	Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1241-1250.	2.0	98



#	ARTICLE	IF	CITATIONS
253	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
254	Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. <i>Seminars in Oncology</i> , 2015, 42, 423-428.	0.8	55
255	Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. <i>Molecular Oncology</i> , 2015, 9, 1918-1935.	2.1	104
256	Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. <i>Clinical Cancer Research</i> , 2015, 21, 4251-4253.	3.2	1
257	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. <i>Molecular Therapy</i> , 2015, 23, 1541-1550.	3.7	93
258	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66.	0.1	151
259	Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization. <i>Journal of Immunology</i> , 2015, 195, 5285-5295.	0.4	66
260	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. <i>Nature Medicine</i> , 2015, 21, 81-85.	15.2	594
261	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA1-LBA1.	0.8	28
262	Abstract 4704: Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma. , 2015, , .		0
263	Clinical Trial Design. , 2014, , 179-201.		0
264	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712.	5.8	503
265	Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype. <i>Human Gene Therapy Methods</i> , 2014, 25, 277-287.	2.1	54
266	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 <sup>+</sup> T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128.	5.8	325
267	Do targeted agents offer clinical benefit as presurgical therapy?. <i>World Journal of Urology</i> , 2014, 32, 3-8.	1.2	16
268	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014, 508, 118-122.	13.7	702
269	Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2014, 110, 2441-2449.	2.9	81
270	Skin-resident memory CD8 <sup>+</sup> T cells trigger a state of tissue-wide pathogen alert. <i>Science</i> , 2014, 346, 101-105.	6.0	444

#	ARTICLE	IF	CITATIONS
271	Acquired and intrinsic resistance in cancer immunotherapy. <i>Molecular Oncology</i> , 2014, 8, 1132-1139.	2.1	153
272	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
273	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58.	2.0	253
274	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
275	Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 538-546.	1.6	29
276	Intradermal Vaccination by DNA Tattooing. <i>Methods in Molecular Biology</i> , 2014, 1143, 131-140.	0.4	11
277	A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4604-TPS4604.	0.8	2
278	Volume of metastases and survival in patients with synchronous metastatic renal cell carcinoma (mRCC) of intermediate Memorial Sloan Kettering Cancer Center (MSKCC) prognosis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15605-e15605.	0.8	0
279	Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. <i>Cancer Treatment Reviews</i> , 2013, 39, 305-312.	3.4	13
280	Transposon leads to contamination of clinical pDNA vaccine. <i>Vaccine</i> , 2013, 31, 3274-3280.	1.7	10
281	High-throughput identification of antigen-specific TCRs by TCR gene capture. <i>Nature Medicine</i> , 2013, 19, 1534-1541.	15.2	166
282	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	0.8	720
283	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2013, 13, 561.	1.1	27
284	The effect of seasonal variation and secretion of sunitinib in sweat on the development of handâ€‘foot syndrome. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2065-2072.	0.8	7
285	Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta OncolÃ³gica</i> , 2013, 52, 1786-1788.	0.8	67
286	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€‘Based Vaccination. <i>Cancer Research</i> , 2013, 73, 19-29.	0.4	131
287	Immunotherapy of melanoma. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 97-105.	2.2	53
288	A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. <i>Annals of Oncology</i> , 2013, 24, 2098-2103.	0.6	41

#	ARTICLE	IF	CITATIONS
289	Vemurafenib As Neoadjuvant Treatment for Unresectable Regional Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e251-e253.	0.8	33
290	Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e439-e442.	0.8	746
291	Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab. <i>Clinical Nuclear Medicine</i> , 2013, 38, e182-e184.	0.7	38
292	Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission. <i>Journal of Clinical Oncology</i> , 2012, 30, e7-e10.	0.8	119
293	TIL therapy broadens the tumor-reactive CD8 <sup>+</sup> T cell compartment in melanoma patients. <i>OncImmunology</i> , 2012, 1, 409-418.	2.1	171
294	Validation of Serum Amyloid A as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. <i>European Urology</i> , 2012, 62, 685-695.	0.9	21
295	Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. <i>Vaccine</i> , 2012, 30, 4259-4266.	1.7	11
296	Modest improvement in 20years of kidney cancer care in the Netherlands. <i>European Journal of Cancer</i> , 2012, 48, 1822-1830.	1.3	8
297	Targeting dendritic cells with antigen via dendritic cell-associated promoters. <i>Cancer Gene Therapy</i> , 2012, 19, 303-311.	2.2	14
298	Tissue-resident memory CD8 <sup>+</sup> T cells continuously patrol skin epithelia to quickly recognize local antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19739-19744.	3.3	230
299	Behavior and Function of Tissue-Resident Memory T cells. <i>Advances in Immunology</i> , 2012, 114, 203-216.	1.1	44
300	Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses. <i>Human Gene Therapy</i> , 2012, 23, 1301-1312.	1.4	32
301	Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. <i>International Journal of Cancer</i> , 2012, 131, E484-93.	2.3	15
302	Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4611-4611.	0.8	1
303	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF <sup>V600E</sup> -mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502.	0.8	86
304	1768 PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC). <i>Journal of Urology</i> , 2011, 185, .	0.2	0
305	Cancer immunotherapy "revisited". <i>Nature Reviews Drug Discovery</i> , 2011, 10, 591-600.	21.5	346
306	A Phase II Study of Presurgical Sunitinib in Patients With Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ. <i>Urology</i> , 2011, 78, 832-837.	0.5	31

#	ARTICLE	IF	CITATIONS
307	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
308	Tilting the AXIS towards therapeutic limits in renal cancer. <i>Lancet, The</i> , 2011, 378, 1898-1900.	6.3	9
309	Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2011, 11, 505.	1.1	25
310	The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2011, 60, 448-454.	0.9	104
311	Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 953-963.	2.0	69
312	Combination of targeted therapy and immunotherapy in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1359-1371.	2.0	40
313	Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. <i>International Journal of Cancer</i> , 2011, 129, 397-406.	2.3	31
314	The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. <i>Annals of Oncology</i> , 2011, 22, 1041-1047.	0.6	85
315	T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 5736-5747.	3.2	33
316	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 620-629.	3.2	150
317	A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). <i>Acta Oncologica</i> , 2011, 50, 121-126.	0.8	36
318	Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4611-4611.	0.8	16
319	DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives. <i>Current Clinical Pharmacology</i> , 2010, 5, 218-225.	0.2	3
320	Naked Plasmid DNA Formulation: Effect of Different Disaccharides on Stability after Lyophilisation. <i>AAPS PharmSciTech</i> , 2010, 11, 344-350.	1.5	23
321	DNA Vaccines and Intradermal Vaccination by DNA Tattooing. <i>Current Topics in Microbiology and Immunology</i> , 2010, 351, 221-250.	0.7	26
322	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1173-1183.	2.0	47
323	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. <i>Journal of Controlled Release</i> , 2010, 141, 234-240.	4.8	67
324	Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant?. <i>International Journal of Pharmaceutics</i> , 2010, 390, 32-36.	2.6	9

#	ARTICLE	IF	CITATIONS
325	Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. <i>Clinical and Experimental Immunology</i> , 2010, 162, 447-459.	1.1	3
326	Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>British Journal of Cancer</i> , 2010, 102, 803-809.	2.9	146
327	Microbead-Assisted Retroviral Transduction for Clinical Application. <i>Human Gene Therapy</i> , 2010, 21, 1335-1342.	1.4	5
328	Re: Surgical Resection of Renal Cell Carcinoma After Targeted Therapy. <i>Journal of Urology</i> , 2010, 183, 1646-1647.	0.2	0
329	Synthetic vehicles for DNA vaccination. <i>Journal of Drug Targeting</i> , 2010, 18, 1-14.	2.1	26
330	Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. <i>Nature Medicine</i> , 2010, 16, 565-570.	15.2	381
331	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
332	Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. <i>Acta Oncologica</i> , 2010, 49, 520-523.	0.8	45
333	Targeted therapy for renal cell cancer: current perspectives. <i>Discovery Medicine</i> , 2010, 10, 394-405.	0.5	28
334	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 4406-4412.	0.8	177
335	Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. <i>Human Gene Therapy</i> , 2009, 20, 181-189.	1.4	54
336	DNA tattoo vaccination: Effect on plasmid purity and transfection efficiency of different topoisomers. <i>Journal of Controlled Release</i> , 2009, 139, 153-159.	4.8	23
337	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. <i>Angiogenesis</i> , 2009, 12, 69-79.	3.7	58
338	Preclinical development of T cell receptor gene therapy. <i>Current Opinion in Immunology</i> , 2009, 21, 209-214.	2.4	48
339	Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 282-288.	1.4	14
340	Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. <i>World Journal of Urology</i> , 2009, 27, 533-539.	1.2	71
341	Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. <i>Nature Methods</i> , 2009, 6, 520-526.	9.0	286
342	Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2009, 101, 1224-1224.	2.9	2

#	ARTICLE	IF	CITATIONS
343	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , 2009, 10, 757-763.	5.1	571
344	Immunotherapeutic strategies: the melanoma example. <i>Immunotherapy</i> , 2009, 1, 679-690.	1.0	9
345	Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2008, 99, 259-265.	2.9	115
346	Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. <i>Vaccine</i> , 2008, 26, 3346-3351.	1.7	45
347	GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 429-438.	2.0	44
348	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892.	3.2	127
349	Cytokine Therapy Response as a Selection Criterion for Cytoreductive Nephrectomy in Metastatic Renal Clear-Cell Carcinoma of Intermediate Prognosis. <i>Urologia Internationalis</i> , 2008, 80, 367-371.	0.6	10
350	Long-Term Functionality of TCR-Transduced T Cells In Vivo. <i>Journal of Immunology</i> , 2008, 180, 6536-6543.	0.4	22
351	An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease. <i>Journal of Immunology</i> , 2008, 180, 6365-6373.	0.4	33
352	Requirements for Effective Antitumor Responses of TCR Transduced T Cells. <i>Journal of Immunology</i> , 2008, 181, 5128-5136.	0.4	52
353	Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer. <i>Cancer Research</i> , 2008, 68, 2455-2462.	0.4	5
354	Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen. <i>Cancer Research</i> , 2008, 68, 8446-8455.	0.4	57
355	Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response. <i>Clinical Cancer Research</i> , 2008, 14, 2431-2436.	3.2	163
356	Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542.	3.2	114
357	T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. <i>Journal of Immunotherapy</i> , 2008, 31, 1-6.	1.2	63
358	Optimization of intradermal vaccination by DNA tattooing in human skin. <i>Human Gene Therapy</i> , 2008, 20, 081125111040089.	1.4	24
359	In Vivo Antigen Stability Affects DNA Vaccine Immunogenicity. <i>Journal of Immunology</i> , 2007, 179, 2126-2133.	0.4	37
360	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. <i>Blood</i> , 2007, 110, 3564-3572.	0.6	95

#	ARTICLE	IF	CITATIONS
361	Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients. <i>Journal of Immunotherapy</i> , 2007, 30, 234-239.	1.2	21
362	Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. <i>BMC Biotechnology</i> , 2007, 7, 2.	1.7	23
363	Vaccine leads to memory loss. <i>Nature Medicine</i> , 2007, 13, 248-250.	15.2	4
364	Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. <i>Laboratory Investigation</i> , 2007, 87, 161-172.	1.7	45
365	Targeting self-antigens through allogeneic TCR gene transfer. <i>Blood</i> , 2006, 108, 870-877.	0.6	61
366	Design and use of conditional MHC class I ligands. <i>Nature Medicine</i> , 2006, 12, 246-251.	15.2	304
367	Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 451-458.	2.0	126
368	In situ visualization of antigen-specific T cells in cryopreserved human tissues. <i>Journal of Immunological Methods</i> , 2006, 310, 78-85.	0.6	12
369	Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. <i>Clinical Cancer Research</i> , 2006, 12, 2826-2833.	3.2	34
370	Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant. <i>Journal of Immunology</i> , 2006, 176, 5213-5222.	0.4	81
371	A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. <i>Nature Medicine</i> , 2005, 11, 899-904.	15.2	153
372	A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 713-719.	2.0	23
373	Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 926-931.	2.0	16
374	Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. <i>European Journal of Cancer</i> , 2005, 41, 386-392.	1.3	42
375	Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice. <i>Cancer Research</i> , 2004, 64, 2153-2161.	0.4	42
376	On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. <i>Clinical Cancer Research</i> , 2004, 10, 4754-4760.	3.2	47
377	Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2657-2662.	3.3	150
378	Ex vivo and in situ detection of tumor-specific T-cell immunity with MHC tetramers. , 2003, , 111-130.		0



#	ARTICLE	IF	CITATIONS
379	Optimizing the Efficacy of Epitope-Directed DNA Vaccination. <i>Journal of Immunology</i> , 2002, 168, 4998-5004.	0.4	36
380	In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. <i>Nature Medicine</i> , 2002, 8, 410-414.	15.2	275
381	A Redundant Role of the CD3 $\zeta$ -Immunoreceptor Tyrosine-Based Activation Motif in Mature T Cell Function. <i>Journal of Immunology</i> , 2001, 166, 2576-2588.	0.4	35
382	Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. <i>European Journal of Immunology</i> , 2000, 30, 1297-1307.	1.6	30
383	Tracing and characterization of the low-avidity self-specific T cell repertoire. <i>European Journal of Immunology</i> , 2000, 30, 1458-1468.	1.6	58
384	In situ detection of virus- and tumor-specific T-cell immunity. <i>Nature Medicine</i> , 2000, 6, 1056-1060.	15.2	78
385	Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants. <i>Journal of Experimental Medicine</i> , 1999, 190, 1319-1328.	4.2	110
386	Systemic T cell expansion during localized viral infection. <i>European Journal of Immunology</i> , 1999, 29, 1168-1174.	1.6	76
387	Clonal dominance and selection for similar complementarity determining region 3 motifs among T lymphocytes responding to the HLA-DR3-associated <i>Mycobacterium leprae</i> heat shock protein 65-KD peptide 3 $\alpha$ 13. <i>Human Immunology</i> , 1995, 44, 220-227.	1.2	16
388	Regulation of Mycobacterial Heat-Shock Protein-Reactive T Cells by HLA Class II Molecules: Lessons from Leprosy. <i>Immunological Reviews</i> , 1991, 121, 171-191.	2.8	61
389	HLA Class-II-restricted <i>Mycobacterium lepraereactive</i> T-Cell Clones from Leprosy Patients Established with a Minimal Requirement for Autologous Mononuclear Cells. <i>Scandinavian Journal of Immunology</i> , 1986, 23, 101-108.	1.3	26